Sangui BioTech Inc., Citadel Investment Systems Inc. deal

Sangui, which develops hemoglobin based hyper-polymer blood substitutes,

Read the full 80 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE